Enzeshu (Suvemcitug) – Ovarian | HongKong DengYue Medicine

Suvemcitug Application Scope

• Indicated for the treatment of platinum-resistant recurrent ovarian cancer

• Also applicable to fallopian tube cancer and primary peritoneal cancer (in combination with paclitaxel, PLD, or topotecan)

Suvemcitug Characteristics

• Ingredients:

  • Active: Suvemcitug

  • Excipients: Standard pharmaceutical excipients

• Properties:​

  • Recombinant humanized monoclonal antibody (anti-angiogenic)

  • Colorless to slightly yellow clear liquid

• Packaging Specification:​ Injection, 50 mg/vial (single-use vial)

• Storage:​

  • Store at 2–8 °C

  • Do not freeze; protect from light

• Expiry Date: 24 months (unopened vial)

• Executive Standard: ​In accordance with NMPA / Pharmacopeia standard

• Approval Number: NMPA-approved (China) S20250037

• Date of Revision: 2025-06-30

• Manufacturer: Simcere Pharmaceutical Group

Guidelines for the Use of Enzeshu

• Dosage and Administration:

  • Recommended Dose: 15 mg/kg IV every 3 weeks (in combination with chemotherapy)

  • Administration:

    • Infuse over 30–90 minutes

    • Do not administer as IV push or bolus

  • Missed Dose:​ Administer as soon as possible, then adjust to maintain schedule

• Adverse Reactions:

  • Common Adverse Reactions:

    • Hypertension

    • Proteinuria

    • Fatigue, diarrhea

  • Serious Adverse Reactions:

    • Gastrointestinal perforation

    • Hemorrhage

    • Arterial/venous thromboembolic events

    • Impaired wound healing

    ​

• Contraindications:

  • Hypersensitivity to it or excipients

  • Recent major surgery or poor wound healing

• Precautions:

  • Monitor blood pressure and urine protein regularly

  • Withhold prior to major surgery

  • Caution in patients with cardiovascular risk factors

Suvemcitug Interactions

• No significant CYP450 drug interactions reported

• Increased bleeding risk with anticoagulants/antiplatelets

• Avoid combination with other anti-angiogenic agents

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.